Faisal Razzaqi
Pediatric Hematology-Oncology · Madera, CANPI 1780875658
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $53,890 of the $76,609 with a category attached, or 70.3%. 24 manufacturers reported payments, led by Sobi, Inc at 58.3% of the total. 2025 is the largest year on record at $31,762, more than ten times the $102 reported in 2019. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $584.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$45K
- Jazz Pharmaceuticals Inc.$24K
- Amgen$7K
- Astellas Pharma US Inc$178
- Novartis$151
- Servier Pharmaceuticals LLC$119
- plus $507 from 18 others
Across 10 payments — averaging $11,470 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$115K
What the payments were for
- Consulting fees$7,1969%
- Speaking & faculty fees$53,89070%
- Travel & lodging$12,62216%
- Food & beverage$2,8534%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 59 | $44,671 |
| Jazz Pharmaceuticals Inc. | 22 | $23,694 |
| Amgen | 9 | $7,288 |
| Astellas Pharma US Inc | 4 | $178 |
| Novartis | 8 | $151 |
| Servier Pharmaceuticals LLC | 5 | $119 |
| RARE Disease Therapeutics, Inc. | 3 | $83 |
| AstraZeneca | 2 | $49 |
| Pharming Healthcare, Inc. | 2 | $40 |
| HEMA Biologics, LLC | 2 | $39 |
| Day One Biopharmaceuticals | 1 | $33 |
| Chiesi USA, Inc. | 2 | $32 |
| Tolmar, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Genetix Biotherapeutics Inc | 1 | $19 |
| Sanofi | 1 | $17 |
| Shorla Oncology Inc. | 1 | $16 |
| Emmaus Medical, Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,609 in reported general payments places this provider in the 90th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Madera
- Vinod BalasaMadera$508K
- Audrey Green-MurphyMadera$77K
- Philip PizzoPalo Alto$2.6M
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
- Vanessa Salinas-LunaOrange$344K
- Daniel KraftStanford$294K
- Arash MahajerinOrange$249K
- Elysia AlvarezPalo Alto$200K
- Christopher DvorakPalo Alto$144K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.